What is the appropriate management of a calcaneal spur in a patient with asthma who is on inhaled corticosteroids and a short‑acting β2‑agonist, while avoiding NSAID‑exacerbated respiratory disease?

Management of Calcaneal Spur in an Asthmatic Patient

For a patient with asthma on inhaled corticosteroids and short-acting β2-agonists who has a calcaneal spur, use local corticosteroid injection for the heel spur while continuing current asthma therapy, avoiding NSAIDs entirely to prevent NSAID-exacerbated respiratory disease.

Treatment Approach for the Calcaneal Spur

Primary Treatment: Local Corticosteroid Injection

Local administration of corticosteroid hormones directly into the calcaneal spur site is highly effective, producing good immediate results in 90% of cases with a single injection, with favorable outcomes persisting long-term in approximately 78% of patients 1. This approach delivers anti-inflammatory therapy precisely where needed without systemic absorption that could complicate asthma management.

Why Avoid NSAIDs

NSAIDs must be completely avoided in this patient. The concern for NSAID-exacerbated respiratory disease (NERD/AERD) is real—these medications can trigger severe bronchospasm, asthma exacerbations, and respiratory symptoms in susceptible individuals 2. Even if the patient has no prior documented NSAID sensitivity, the risk-benefit ratio strongly favors avoidance given safer alternatives exist for heel pain.

Asthma Management Considerations

Current Regimen Assessment

The patient is currently on inhaled corticosteroids plus a short-acting β2-agonist (SABA). This represents inadequate therapy for most patients beyond intermittent asthma. If the patient requires SABA more than 2 days per week for symptom relief (excluding exercise-induced bronchospasm prevention), this indicates inadequate asthma control and necessitates stepping up anti-inflammatory therapy 3.

Recommended Asthma Therapy Optimization

Step up to combination ICS-LABA therapy if asthma is not fully controlled:

• For moderate persistent asthma (Step 3), the preferred treatment is low-to-medium dose inhaled corticosteroid plus long-acting inhaled β2-agonist 4, 3
• This combination provides superior asthma control compared to doubling ICS doses alone 4
• ICS-LABA combinations demonstrate synergistic anti-inflammatory and bronchodilator effects 3

Alternative option if ICS-LABA unavailable:

• Increase ICS to medium-dose range as monotherapy 4
• Add leukotriene receptor antagonist (montelukast or zafirlukast) to low-medium dose ICS 3

Critical Monitoring Parameters

• Assess SABA use frequency—using more than 2 days/week signals poor control 3
• Check inhaler technique and adherence before escalating therapy 4
• Evaluate for environmental triggers and comorbidities 3
• Monitor for nocturnal symptoms or activity limitation

Practical Implementation Algorithm

For the heel spur:

1. Perform local corticosteroid injection (single administration typically sufficient)
2. Reassess at 2-4 weeks for symptom resolution
3. Repeat injection if needed (most patients respond to single dose)

For asthma optimization:

1. Evaluate current SABA use frequency and symptom patterns
2. If using SABA >2 days/week or having nocturnal symptoms → Step up to ICS-LABA combination
3. If already well-controlled on current regimen → Continue ICS + SABA as needed
4. Follow up every 2-4 weeks initially, then every 1-3 months once stable 5

Key Pitfalls to Avoid

Do not prescribe oral NSAIDs for the heel spur—the respiratory risks outweigh benefits when effective alternatives exist. Even COX-2 selective inhibitors carry risk in asthma patients.

Do not use SABA monotherapy as the sole asthma treatment if symptoms occur more than intermittently. Recent evidence strongly supports that SABAs should not be used as reliever therapy without ICS 6, 7. Consider switching to as-needed low-dose ICS-formoterol for both maintenance and relief if symptoms are infrequent 8, 7.

Do not assume the local corticosteroid injection will worsen asthma control—the systemic absorption from a single local injection is minimal and should not impact respiratory status, unlike oral corticosteroids which require careful monitoring.

Verify inhaler technique before assuming treatment failure—incorrect technique is a common cause of apparent poor asthma control 4, 5.